Resources
About Us
Home Report
Store
Rapid Diagnostics Market
Rapid Diagnostics Market Size, Share, Forecast, & Trends Analysis by Product (Kits [OTC, Professional], Readers) Platform (Lateral Flow, Serological, PCR) Application (Diabetes, Infectious Diseases, Pregnancy, HIV) Sample (Blood) - Global Forecast to 2031
Report ID:MRHC - 104553 Pages: 260 Sep-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 48 HoursThe Rapid Diagnostics Market was valued at $14.74 billion in 2023. This market is expected to reach $22.65 billion by 2031 from an estimated $14.57 billion in 2024, at a CAGR of 6.5% during the forecast period from 2024 to 2031.
Rapid Diagnostics Market Size & Forecast
RDT kits are extensively utilized in hospitals and clinical laboratories for the qualitative and quantitative detection of specific antigens, antibodies, and genetic material or proteins related to particular health conditions or diseases. These kits help uncover the underlying mechanisms of disease and empower doctors and healthcare professionals to make critical medical decisions.
The rapid growth of the rapid diagnostics market is driven by several key factors, including the increasing demand for point-of-care (POC) diagnostics, the rising prevalence of chronic diseases alongside an aging population, the need for swift decision-making in emergency departments, and ongoing technological innovations.
Rapid Diagnostics Market Growth Drivers
Rising Prevalence of Infectious Diseases
The exponential growth of the human population has resulted in the expansion of human settlements into new geographical areas, increasing the likelihood of contact with animals that may serve as potential hosts for infectious disease agents. This phenomenon has contributed to the emergence of various infectious diseases throughout history. Additionally, there is a rising prevalence of infectious diseases on a global scale. For example, a July 2022 article in the United Nations’ Africa Renewal digital magazine highlighted that the risk of outbreaks caused by zoonotic pathogens, such as the Ebola and monkeypox viruses, is increasing. According to the WHO, there has been a 63% rise in zoonotic disease outbreaks in Africa from 2012 to 2022 compared to the period from 2001 to 2011.
- In September 2023, the Ministry of Health and Family Welfare of India reported six confirmed cases of the Nipah virus in the state of Kerala. As of September 27, 2024, 1,288 contact cases related to the Nipah virus have been reported.
- The global epidemiological burden of sepsis has risen significantly in recent years. According to the WHO, sepsis is estimated to affect over 30 million people worldwide, resulting in approximately 6 million deaths annually.
- In 2021, approximately 38.4 million people were living with HIV, including 1.7 million children. Of this total, 20.6 million (53%) resided in eastern and southern Africa, 5 million (13%) in western and central Africa, 6 million (15%) in Asia and the Pacific, and 2.3 million (5%) in Western and Central Europe and North America.
Rapid diagnostic tests enable the early detection of infectious diseases, which is valuable for controlling their spread. The rising prevalence and outbreaks of infectious diseases are expected to drive the market's growth.
Increasing Need for Rapid Decision-making
Emergency departments in hospitals play a vital role in delivering both inpatient and outpatient services, essential for preventing death or serious health impairment. However, overcrowding in these departments is a well-documented challenge, driven by factors such as the increasing geriatric population and referrals from primary care. To address this issue, rapid diagnostics are being increasingly adopted in emergency departments to improve clinical decision-making related to patient diagnosis, treatment, monitoring, and prognosis. This approach also aims to optimize resource utilization and alleviate overcrowding. The rising number of patient admissions in emergency departments globally further fuels the demand for rapid diagnostic kits.
Rapid Diagnostics Market Trends
Lateral Flow Assays Containing DNA Nanostructures
A lateral flow assay is a rapid diagnostic test designed to confirm the presence or absence of target analytes, such as pathogens or biomarkers, in human samples like blood, serum, urine, or saliva. These assays utilize antibodies on a conjugate pad that bind to the target antigen to generate results. Traditional antibodies can be substituted with DNA nanostructures that offer high binding affinity and specificity for the target antigen. For instance, Atom Bioworks Inc. (U.S.) has developed the DNA Star Rapid Diagnostics Platform, a lateral flow assay kit that incorporates nanoengineered DNA nanostructures instead of conventional antibodies. In 2021, the company received the Rapid Testing Innovation Award at the Advanced Lateral Flow Conference organized by DCN Diagnostics (U.S.) and DIALUNOX GmbH (Germany).
Smartphone-based Detection Platforms
The demand for high-quality medical services continues to rise. Technological advancements, such as portable devices for use at home or in remote areas, significantly enhance both the quantity and quality of medical care. Smartphone-based platforms are increasingly applied in tele-imaging, food technology, and education, demonstrating their versatility across various medical applications. Rapid diagnostics are crucial for screening patients in any healthcare setting. Given the high costs of diagnosis and the limited availability of benchtop readers in resource-constrained areas, the demand for smartphone-based rapid diagnostics is steadily increasing.
Many companies in the rapid diagnostics market are developing smartphone-based, end-to-end platforms that integrate with mobile applications to streamline test result generation in point-of-care environments. These platforms often incorporate deep learning methods to improve device efficiency. Additionally, smartphone-based detection methods facilitate automated result detection and analysis while supporting human expertise. Patient data transactions are secured and validated through blockchain technology, ensuring trust and security in data handling.
Rapid Diagnostics Market Opportunity
Emerging Markets
Emerging economies worldwide are driving demand for healthcare services and treatments due to rapid urbanization, improving healthcare infrastructure and expenditures, expanding health insurance coverage, rising disposable incomes, and a growing prevalence of both non-communicable and infectious diseases.
According to the International Diabetes Federation, in 2021, the number of individuals with diabetes in middle-income countries—including China, Brazil, Bangladesh, India, and Indonesia—was 414 million. This figure is projected to rise to 623.3 million by 2045. Additionally, the World Health Organization reported in May 2022 that, in low- and middle-income countries, 15 out of every 100 patients in acute-care hospitals acquire at least one healthcare-associated infection (HAI) during their hospital stay, with one out of ten of these infections leading to mortality.
Rapid Diagnostics Market Study: Key Findings
The Kits Segment to Account for a Large Share of the Rapid Diagnostics Market in 2024
Based on product, the rapid diagnostics market is segmented into kits and equipment. In 2024, the kits segment is expected to account for the largest share of 67.6% of the rapid diagnostics market. The significant share of this segment can be attributed to the increasing adoption and frequent use of kits. Additionally, the expanding portfolio of disease-specific rapid kits for the early diagnosis of chronic and infectious diseases, along with ongoing technological advancements, further supports the segment's substantial market share. Moreover, this segment is expected to register the highest CAGR of 7.2% during the forecast period.
The Immunoassay Segment to Account for a Large Share of the Rapid Diagnostics Market in 2024
Based on platform, the rapid diagnostics market is segmented into immunoassays, molecular detection tests, and other rapid diagnostic platforms. In 2024, the immunoassay segment is expected to account for the largest share of 54.2% of the rapid diagnostics market. The substantial share of this segment can be attributed to the high prevalence of infectious and chronic diseases, the lower costs of rapid immunoassay tests compared to traditional laboratory-based tests, ongoing technological innovations, and the increasing demand for lateral flow assay kits suitable for home use.
However, the molecular detection tests segment is expected to register the highest CAGR of 6.2% during the forecast period. The factors driving the segment growth are the high sensitivity and accuracy of these tests, the growing need for advanced diagnostic techniques, and the widening applications of molecular detection tests in various fields.
The Infectious Disease Segment to Account for a Large Share of the Rapid Diagnostics Market in 2024
Based on application, the rapid diagnostics market is segmented into blood glucose testing, cardiac metabolism testing, infectious diseases testing, pregnancy & fertility testing, hematology testing, tumor/cancer markers testing, urinalysis, cholesterol testing, and other tests. In 2024, the infectious disease segment is expected to account for the largest share of the rapid diagnostics market. The large share of this segment is mainly attributed to the rising prevalence of infectious diseases, high awareness, and major efforts regarding early diagnosis, monitoring, and surveillance of infectious diseases after the COVID-19 pandemic.
However, the tumor/cancer markers testing segment is expected to register the highest CAGR during the forecast period. The factors attributed to this segment’s growth are the rising prevalence of cancer worldwide, growing investments and funding for cancer biomarker research, and advancements in cancer diagnostic technologies.
The Blood Segment to Account for the Largest Share of the Rapid Diagnostics Market in 2024
Based on sample type, the rapid diagnostics market is segmented into blood, saliva, nasal, and oropharyngeal, urine, and other samples. In 2024, the blood segment is expected to account for the largest share of the market. The large share of this segment is attributed to the high availability of rapid tests requiring blood as the sample, the high tendency of the blood samples to retain the genetic material intact without altering its properties compared to other samples, and easy extraction and storage options for blood samples.
Moreover, the blood segment is expected to register the highest CAGR during the forecast period due to players' growing focus on launching rapid tests that require blood samples.
The Hospitals & Clinics Segment to Account for the largest share of the Rapid Diagnostics Market in 2024
Based on end user, the rapid diagnostics market is segmented into hospitals & clinics, diagnostic laboratories, home care/self-testing, and other end users. In 2024, the hospitals & clinics segment is estimated to account for the largest share of the rapid diagnostics market. The large share of this segment is mainly attributed to the increasing number of patient visits to hospitals for various healthcare services, such as diagnosis, treatments, and surgeries with well-equipped operating & diagnostic rooms, the presence of highly skilled healthcare professionals, the ease of accessibility, and better health coverage for hospital-based healthcare services from various private and group insurance plans.
However, the home care/self-testing segment is expected to register the highest CAGR during the forecast period. The rising incidence of chronic diseases necessitating ongoing care and regular monitoring, coupled with the expanding utilization of home healthcare services and the enhanced availability of accessible and advanced point-of-care diagnostic products, are key drivers fueling the demand for rapid diagnostics in home environments.
Geographical Analysis
Based on geography, the rapid diagnostics market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. In 2024, North America is expected to account for the largest share of 41% of the rapid diagnostics market. The large share of North America is attributed to the region’s highly developed diagnostic infrastructure, the high number of laboratory tests performed annually, the rising prevalence of chronic diseases coupled with growth in the aging population, the rising number of inpatient admissions, increasing awareness, and the growing adoption of self-testing kits among the general population.
However, Asia-Pacific is expected to be the fastest-growing regional market, registering a CAGR of 10.1% during the forecast period. The aging population, the rising prevalence of infectious and chronic diseases, and various government initiatives to promote health awareness drive the rapid diagnostics market in Asia-Pacific.
Rapid Diagnostics Market: Key Companies
The report includes a competitive landscape based on an extensive assessment of the key growth strategies adopted by leading market participants in the last three to four years. The key players profiled in the rapid diagnostics market report include Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), ACON Laboratories, Inc. (U.S.), Creative Diagnostics (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), BioMérieux S.A. (France), Alfa Scientific Designs, Inc. (U.S.), BTNX Inc. (Canada), Meridian Bioscience, Inc. (U.S.), and Trinity Biotech plc (Ireland).
Rapid Diagnostics Market Industry Overview: Latest Developments from Key Industry Players
- In February 2024, Bio-Rad Laboratories Inc. (U.S.) launched the Vericheck ddPCR Replication Competent Lentivirus Kit and the Vericheck ddPCR Replication Competent AAV Kit. These provide rapid results for absolute quantification of replication-competent lentivirus (RCL) and replication-competent adeno-associated virus.
- In March 2023, Abbott Laboratories (U.S.) received approval from the U.S. FDA for the company’s new traumatic brain injury (TBI) blood test.
- In February 2023, Beckton, Dickinson, and Company (U.S.) received emergency use approval from the U.S. FDA for its new molecular diagnostic combination test for SARS-CoV-2, Influenza A + B, and Respiratory Syncytial Virus (RSV).
Rapid Diagnostics Market Research Summary
|
Particular |
Details |
|
No of Pages |
260 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2023 |
|
CAGR |
6.5% |
|
Market Size (Value) |
$22.65 Billion by 2031 |
|
Segments Covered |
By Product
By Platform
By Application
by Sample Type
End User
|
|
Countries Covered |
North America (U.S., Canada), Europe (Germany, France, U.K., Spain, Italy, Switzerland, Sweden, Netherlands, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of APAC), Latin America (Brazil, Mexico, Rest of Latin America), and Middle East & Africa (Saudi Arabia, South Africa, and Rest of Middle East & Africa) |
|
Key Companies |
Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), ACON Laboratories, Inc. (U.S.), Creative Diagnostics (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), BioMérieux S.A. (France), Alfa Scientific Designs, Inc. (U.S.), BTNX Inc. (Canada), Meridian Bioscience, Inc. (U.S.), and Trinity Biotech plc (Ireland) |
Key questions answered in the Rapid Diagnostics Market report:
The rapid diagnostics market covers the market sizes & forecasts for the various rapid diagnostic kits used for blood glucose testing, cardiac metabolism testing, infectious diseases testing, coagulation testing, pregnancy & fertility testing, fecal occult testing, hematology testing, tumor/cancer markers testing, drugs of abuse testing, urinalysis, and cholesterol testing. The rapid diagnostics market studied in this report involves the value analysis of various segments and subsegments of rapid diagnostic kit producers at the regional and country levels.
The rapid diagnostics market is projected to reach $22.65 billion by 2031, at a CAGR of 6.5% during the forecast period.
Based on product, the kits segment is estimated to account for the largest share of the rapid diagnostics market in 2024. This segment's large share is attributed to its rising adoption and repetitive kit usage. In addition, the growing portfolio of disease-specific kits for the early diagnosis of chronic diseases and the increasing technological advancements are other factors supporting its growth.
The hospitals and clinics segment is estimated to register the fastest CAGR during the forecast period due to the increasing number of patient visits to hospitals for various healthcare services, the presence of highly skilled healthcare professionals, the ease of accessibility, and better health coverage for hospital-based healthcare services from various private and group insurance plans.
The growing demand for POC diagnostics, emerging technological innovations, the growing prevalence of infectious diseases, the rising prevalence of chronic diseases coupled with the increasing aging population, and the growing necessity for rapid decision-making in emergency departments are the key factors driving the growth of the rapid diagnostics market. Furthermore, the growing market potential in emerging economies, such as China and India, provides significant opportunities for existing market players and new entrants in this market.
The key players operating in the rapid diagnostics market are Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), ACON Laboratories, Inc. (U.S.), Creative Diagnostics (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), BioMérieux S.A. (France), Scientific Designs, Inc. (U.S.), BTNX Inc. (Canada), Meridian Bioscience, Inc. (U.S.), and Trinity Biotech plc (Ireland).
Emerging economies from Asia, such as China and India, are projected to offer significant growth opportunities for companies operating in this market. Additionally, the rising number of people suffering from non-communicable and infectious diseases, the growing population, and rising urbanization are factors expected to offer significant growth opportunities in this region.
1. Overview
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency and Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing and Forecast
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions For the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Drivers
4.2.1. Rising Prevalence of Chronic Diseases Coupled with the Increasing Geriatric Population
4.2.2. Growing Prevalence of Infectious Diseases
4.2.3. Increasing Need for Rapid Decision-making
4.2.4. Growing Demand for Point-of-Care (POC) Diagnostics
4.2.5. Technological Innovations
4.3. Restraints
4.3.1. Variance in Test Results
4.3.2. Availability of Alternative Products
4.4. Opportunities
4.4.1. High Growth Prospects in Emerging Countries
4.5. Challenges
4.5.1. Reluctance Toward Changing Existing Diagnostic Practices
4.5.2. Interpretation of Results Obtained by OTC Rapid Tests
4.6. Regulatory Affairs Analysis
4.6.1. North America
4.6.1.1. U.S.
4.6.1.2. Canada
4.6.2. Europe
4.6.3. Asia-Pacific
4.6.3.1. Japan
4.6.3.2. China
4.6.3.3. Japan
4.6.4. Latin America
4.6.5. Middle East & Africa
4.7. Technology Trends
4.7.1. Lateral Flow Assays Containing DNA Nanostructures
4.7.2. Smartphone-based Detection Platforms
4.7.3. Nano-electronic Biosensors in Rapid Diagnostics
4.8. Porter's Five Forces Analysis
4.9. Pricing Analysis
4.10. Parent Market Analysis
4.10.1. Global IVD Market Overview
4.10.2. Global Molecular Diagnostics Market Overview
4.10.3. Global Immunoassay Market Overview
4.11. Macroindicators
4.11.1. Diabetes Prevalence, by Region (2021 vs 2045)
4.11.2. Cancer Prevalence, by Region X Cancer Type (2022-2030)
4.11.3. Infectious Disease Outbreaks, by Region (2021-2024)
4.11.4. Global Fertility Rate (2018-2022)
4.11.5. Global Trends in HIV Infections and Mortalities (2023-2030)
4.12. Technology Evolution
4.13. Value Chain Analysis
4.14. Consumer Behavior Analysis
4.14.1. Vendor Selection Criteria
4.14.2. Unmet Needs
4.14.3. Vendor/Brand Analysis
4.14.4. Product/Technology Adoption Trends
5. Rapid Diagnostics Market—by Product
5.1. Overview
5.2. Kits
5.2.1. OTC Kits
5.2.2. Professional Kits
5.3. Equipment
6. Rapid Diagnostics Market—by Platform
6.1. Overview
6.2. Immunoassays
6.2.1. Lateral Flow Assays
6.2.2. Serological Assays
6.2.3. Other Immunoassays
6.3. Molecular Detection
6.3.1. RT-PCR
6.3.2. Isothermal Nucleic Acid Amplification Technology (INAAT)
6.4. Other Rapid Diagnostic Platforms
7. Rapid Diagnostics Market, by Application
7.1. Overview
7.2. Blood Glucose Testing
7.3. Cardiac Metabolism Testing
7.4. Infectious Disease Testing
7.4.1. Influenza Testing
7.4.2. HIV Testing
7.4.3. Hepatitis Testing
7.4.3.1. Hepatitis B
7.4.3.2. Hepatitis C
7.4.4. Sexually Transmitted Disease (STD) Testing
7.4.5. Healthcare Associated Infection (HAI) Testing
7.4.6. Respiratory Disease Testing
7.4.7. Tropical Disease Testing
7.4.8. Other Infectious Disease Testing
7.5. Pregnancy and Fertility Testing
7.6. Hematology Testing
7.7. Tumor/Cancer Markers Testing
7.8. Urinalysis
7.9. Cholesterol Testing
7.10. Other Applications
8. Rapid Diagnostics Market—by Sample Type
8.1. Overview
8.2. Blood
8.3. Saliva, Nasal and Oropharyngeal
8.4. Urine
8.5. Other Samples
9. Rapid Diagnostics Market—by End User
9.1. Overview
9.2. Hospital & Clinics
9.3. Diagnostic Laboratories
9.4. Home Care/Self-Testing
9.5. Other End Users
10. Rapid Diagnostics Market—by Geography
10.1. Overview
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. Germany
10.3.2. U.K.
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Sweden
10.3.7. Switzerland
10.3.8. Netherlands
10.3.9. Rest of Europe
10.4. Asia-Pacific
10.4.1. Japan
10.4.2. China
10.4.3. India
10.4.4. South Korea
10.4.5. Australia
10.4.6. Rest of Asia-Pacific
10.5. Latin America
10.5.1. Brazil
10.5.2. Mexico
10.5.3. Rest of Latin America
10.6. Middle East & Africa
10.6.1. Saudi Arabia
10.6.2. South Africa
10.6.3. Rest of Middle East & Africa
11. Competition Analysis
11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
11.4.1. Industry Leaders
11.4.2. Market Differentiators
11.4.3. Vanguards
11.4.4. Emerging Companies
11.5. Market Share Analysis, by Key Players (2023)
11.6. List of Key Distributors for Rapid Diagnostic Products, by Region
12. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)
12.1. Abbott Laboratories
12.2. Becton, Dickinson and Company (BD)
12.3. Bio-Rad Laboratories, Inc.
12.4. F. Hoffmann-La Roche Ltd
12.5. Acon Laboratories, Inc.
12.6. Creative Diagnostics
12.7. Danaher Corporation
12.8. Thermo Fisher Scientific Inc.
12.9. Biomérieux S.A.
12.10. Alfa Scientific Designs, Inc.
12.11. Btnx Inc.
12.12. Meridian Bioscience, Inc.
12.13. Trinity Biotech Plc
(Note: SWOT Analysis of the Top 5 Companies Will Be Provided)
13. Appendix
13.1. Available Customization
13.2. Related Reports
List of Tables
Table 1 Global Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 2 Global Rapid Diagnostic Kits Market, by Type, 2022–2031 (USD Million)
Table 3 Global Rapid Diagnostic Kits Market, by Country/Region, 2022–2031 (USD Million)
Table 4 Global Rapid Diagnostic OTC Kits Market, by Country/Region, 2022–2031 (USD Million)
Table 5 Global Rapid Diagnostic Professional Kits Market, by Country/Region, 2022–2031 (USD Million)
Table 6 Global Rapid Diagnostic Test Readers/Analyzers Market, by Country/Region, 2022–2031 (USD Million)
Table 7 Global Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 8 Global Immunoassays Market, by Type, 2022–2031 (USD Million)
Table 9 Global Immunoassays Market, by Country/Region, 2022–2031 (USD Million)
Table 10 Global Lateral Flow Assays Market, by Country/Region, 2022–2031 (USD Million)
Table 11 Global Serological Assays Market, by Country/Region, 2022–2031 (USD Million)
Table 12 Global Other Immunoassays Market, by Country/Region, 2022–2031 (USD Million)
Table 13 Global Molecular Detection Market, by Type, 2022–2031 (USD Million)
Table 14 Global Molecular Detection Market, by Country/Region, 2022–2031 (USD Million)
Table 15 Global Polymerase Chain Reaction (PCR) Market, by Country/Region, 2022–2031 (USD Million)
Table 16 Global Isothermal Nucleic Acid Amplification Technology (INAAT) Market, by Country/Region, 2022–2031 (USD Million)
Table 17 Global Other Platforms Market, by Country/Region, 2022–2031 (USD Million)
Table 18 Global Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 19 Global Rapid Diagnostics Market Size for Blood Glucose Testing, by Country/Region, 2022–2031 (USD Million)
Table 20 Global Rapid Diagnostics Market Size for Cardiac Metabolism Testing, by Country/Region, 2022–2031 (USD Million)
Table 21 Global Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 22 Global Rapid Diagnostics Market Size for Infectious Disease Testing, by Country/Region, 2022–2031 (USD Million)
Table 23 Global Rapid Diagnostics Market Size for Influenza Testing, by Country/Region, 2022–2031 (USD Million)
Table 24 Global Rapid Diagnostics Market Size for HIV Testing, by Country/Region, 2022–2031 (USD Million)
Table 25 Global Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 26 Global Rapid Diagnostics Market Size for Hepatitis Testing, by Country/Region, 2022–2031 (USD Million)
Table 27 Global Rapid Diagnostics Market Size for Hepatitis B Testing, by Country/Region, 2022–2031 (USD Million)
Table 28 Global Rapid Diagnostics Market Size for Hepatitis C Testing, by Country/Region, 2022–2031 (USD Million)
Table 29 Global Rapid Diagnostics Market Size for Sexually Transmitted Disease (STD) Testing, by Country/Region, 2022–2031 (USD Million)
Table 30 Global Rapid Diagnostics Market Size for Healthcare Associated Infection (HAI) Testing, by Country/Region, 2022–2031 (USD Million)
Table 31 Global Rapid Diagnostics Market Size for Respiratory Disease Testing, by Country/Region, 2022–2031 (USD Million)
Table 32 Global Rapid Diagnostics Market Size for Tropical Disease Testing, by Country/Region, 2022–2031 (USD Million)
Table 33 Global Rapid Diagnostics Market Size for Other Infectious Disease Testing, by Country/Region, 2022–2031 (USD Million)
Table 34 Global Rapid Diagnostics Market Size for Pregnancy and Fertility Testing, by Country/Region, 2022–2031 (USD Million)
Table 35 Global Rapid Diagnostics Market Size for Hematology Testing, by Country/Region, 2022–2031 (USD Million)
Table 36 Global Rapid Diagnostics Market Size for Tumor/Cancer Markers Testing, by Country/Region, 2022–2031 (USD Million)
Table 37 Global Rapid Diagnostics Market Size for Urinalysis, by Country/Region, 2022–2031 (USD Million)
Table 38 Global Rapid Diagnostics Market Size for Cholesterol Testing, by Country/Region, 2022–2031 (USD Million)
Table 39 Global Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 40 Global Rapid Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 41 Global Rapid Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 42 Global Rapid Diagnostics Market for blood sample, by Country/Region, 2022–2031 (USD Million)
Table 43 Global Rapid Diagnostics Market for Saliva, Nasal, and Oropharyngeal Sample, by Country/Region, 2022–2031 (USD Million)
Table 44 Global Rapid Diagnostics Market for Urine Sample, by Country/Region, 2022–2031 (USD Million)
Table 45 Global Rapid Diagnostics Market for Other Sample Types, by Country/Region, 2022–2031 (USD Million)
Table 46 Global Rapid Diagnostics Market, by End User (2022–2031) (USD Million)
Table 47 Global Rapid Diagnostics Market Size for Hospitals & Clinics, by Country/Region, 2022–2031 (USD Million)
Table 48 Global Rapid Diagnostics Market Size for Diagnostic Laboratories, by Country/Region, 2022–2031 (USD Million)
Table 49 Global Rapid Diagnostics Market Size for Home Care/Self-Testing, by Country/Region, 2022–2031 (USD Million)
Table 50 Global Rapid Diagnostics Market Size for Other End Users, by Country/Region, 2022–2031 (USD Million)
Table 51 Rapid Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 52 North America: Rapid Diagnostics Market, by Country, 2022–2031 (USD Million)
Table 53 North America: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 54 North America: Rapid Diagnostic Kits Market, by Type, 2022–2031 (USD Million)
Table 55 North America: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 56 North America: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 57 North America: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 58 North America: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 59 North America: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 60 North America: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 61 North America: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 62 North America: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 63 U.S.: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 64 U.S.: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 65 U.S.: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 66 U.S.: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 67 U.S.: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 68 U.S.: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 69 U.S.: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 70 U.S.: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 71 U.S.: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 72 U.S.: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 73 Canada: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 74 Canada: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 75 Canada: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 76 Canada: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 77 Canada: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 78 Canada: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 79 Canada: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 80 Canada: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 81 Canada: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 82 Canada: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 83 Europe: Rapid Diagnostics Market, by Country, 2022–2031 (USD Million)
Table 84 Europe: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 85 Europe: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 86 Europe: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 87 Europe: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 88 Europe: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 89 Europe: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 90 Europe: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 91 Europe: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 92 Europe: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 93 Europe: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 94 Germany: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 95 Germany: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 96 Germany: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 97 Germany: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 98 Germany: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 99 Germany: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 100 Germany: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 101 Germany: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 102 Germany: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 103 Germany: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 104 U.K.: Number of Chlamydia Tests Conducted, 2018–2019
Table 105 U.K.: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 106 U.K.: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 107 U.K.: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 108 U.K.: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 109 U.K.: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 110 U.K.: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 111 U.K.: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 112 U.K.: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 113 U.K.: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 114 U.K.: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 115 France: Estimated Number of Household Pets, 2017–2019
Table 116 France: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 117 France: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 118 France: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 119 France: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 120 France: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 121 France: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 122 France: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 123 France: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 124 France: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 125 France: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 126 Italy: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 127 Italy: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 128 Italy: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 129 Italy: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 130 Italy: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 131 Italy: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 132 Italy: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 133 Italy: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 134 Italy: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 135 Italy: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 136 Spain: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 137 Spain: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 138 Spain: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 139 Spain: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 140 Spain: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 141 Spain: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 142 Spain: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 143 Spain: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 144 Spain: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 145 Spain: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 146 Sweden: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 147 Sweden: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 148 Sweden: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 149 Sweden: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 150 Sweden: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 151 Sweden: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 152 Sweden: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 153 Sweden: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 154 Sweden: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 155 Sweden: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 156 Switzerland: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 157 Switzerland: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 158 Switzerland: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 159 Switzerland: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 160 Switzerland: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 161 Switzerland: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 162 Switzerland: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 163 Switzerland: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 164 Switzerland: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 165 Switzerland: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 166 Netherlands: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 167 Netherlands: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 168 Netherlands: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 169 Netherlands: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 170 Netherlands: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 171 Netherlands: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 172 Netherlands: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 173 Netherlands: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 174 Netherlands: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 175 Netherlands: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 176 Rest of Europe: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 177 Rest of Europe: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 178 Rest of Europe: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 179 Rest of Europe: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 180 Rest of Europe: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 181 Rest of Europe: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 182 Rest of Europe: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 183 Rest of Europe: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 184 Rest of Europe: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 185 Rest of Europe: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 186 Asia-Pacific: Rapid Diagnostics Market, by Country, 2022–2031 (USD Million)
Table 187 Asia-Pacific: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 188 Asia-Pacific: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 189 Asia-Pacific: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 190 Asia-Pacific: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 191 Asia-Pacific: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 192 Asia-Pacific: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 193 Asia-Pacific: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 194 Asia-Pacific: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 195 Asia-Pacific: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 196 Asia-Pacific: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 197 Japan: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 198 Japan: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 199 Japan: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 200 Japan: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 201 Japan: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 202 Japan: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 203 Japan: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 204 Japan: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 205 Japan: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 206 Japan: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 207 China: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 208 China: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 209 China: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 210 China: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 211 China: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 212 China: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 213 China: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 214 China: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 215 China: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 216 China: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 217 India: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 218 India: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 219 India: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 220 India: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 221 India: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 222 India: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 223 India: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 224 India: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 225 India: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 226 India: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 227 South Korea: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 228 South Korea: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 229 South Korea: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 230 South Korea: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 231 South Korea: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 232 South Korea: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 233 South Korea: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 234 South Korea: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 235 South Korea: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 236 Australia: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 237 Australia: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 238 Australia: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 239 Australia: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 240 Australia: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 241 Australia: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 242 Australia: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 243 Australia: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 244 Australia: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 245 Rest of Asia-Pacific: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 246 Rest of Asia-Pacific: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 247 Rest of Asia-Pacific: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 248 Rest of Asia-Pacific: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 249 Rest of Asia-Pacific: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 250 Rest of Asia-Pacific: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 251 Rest of Asia-Pacific: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 252 Rest of Asia-Pacific: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 253 Rest of Asia-Pacific: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 254 Rest of Asia-Pacific: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 255 Latin America: Rapid Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 256 Latin America: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 257 Latin America: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 258 Latin America: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 259 Latin America: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 260 Latin America: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 261 Latin America: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 262 Latin America: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 263 Latin America: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 264 Latin America: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 265 Latin America: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 266 Brazil: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 267 Brazil: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 268 Brazil: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 269 Brazil: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 270 Brazil: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 271 Brazil: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 272 Brazil: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 273 Brazil: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 274 Brazil: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 275 Brazil: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 276 Mexico: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 277 Mexico: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 278 Mexico: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 279 Mexico: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 280 Mexico: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 281 Mexico: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 282 Mexico: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 283 Mexico: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 284 Mexico: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 285 Latin America: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 286 Rest of Latin America: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 287 Rest of Latin America: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 288 Rest of Latin America: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 289 Rest of Latin America: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 290 Rest of Latin America: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 291 Rest of Latin America: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 292 Rest of Latin America: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 293 Rest of Latin America: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 294 Rest of Latin America: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 295 Rest of Latin America: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 296 Middle East & Africa: Rapid Diagnostics Market, by Country/Region, 2022–2031 (USD Million)
Table 297 Middle East & Africa: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 298 Middle East & Africa: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 299 Middle East & Africa: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 300 Middle East & Africa: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 301 Middle East & Africa: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 302 Middle East & Africa: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 303 Middle East & Africa: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 304 Middle East & Africa: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 305 Middle East & Africa: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 306 Middle East & Africa: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 307 Saudi Arabia: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 308 Saudi Arabia: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 309 Saudi Arabia: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 310 Saudi Arabia: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 311 Saudi Arabia: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 312 Saudi Arabia: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 313 Saudi Arabia: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 314 Saudi Arabia: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 315 Saudi Arabia: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 316 Saudi Arabia: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 317 South Africa: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 318 South Africa: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 319 South Africa: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 320 South Africa: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 321 South Africa: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 322 South Africa: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 323 South Africa: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 324 South Africa: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 325 South Africa: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 326 South Africa: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 327 Rest of Middle East & Africa: Rapid Diagnostics Market, by Product, 2022–2031 (USD Million)
Table 328 Rest of Middle East & Africa: Rapid Diagnostics Kits Market, by Type, 2022–2031 (USD Million)
Table 329 Rest of Middle East & Africa: Rapid Diagnostics Market, by Platform, 2022–2031 (USD Million)
Table 330 Rest of Middle East & Africa: Immunoassays Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 331 Rest of Middle East & Africa: Molecular Detection Based Rapid Diagnostics Market, by Type, 2022–2031 (USD Million)
Table 332 Rest of Middle East & Africa: Rapid Diagnostics Market, by Application, 2022–2031 (USD Million)
Table 333 Rest of Middle East & Africa: Rapid Diagnostics Market Size for Infectious Disease Testing, by Type, 2022–2031 (USD Million)
Table 334 Rest of Middle East & Africa: Rapid Diagnostics Market Size for Hepatitis Testing, by Type, 2022–2031 (USD Million)
Table 335 Rest of Middle East & Africa: Rapid Diagnostics Market, by Sample Type, 2022–2031 (USD Million)
Table 336 Rest of Middle East & Africa: Rapid Diagnostics Market, by End User, 2022–2031 (USD Million)
Table 337 Recent Developments, by Company, 2021-2024
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply Side & Demand Side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Global Rapid Diagnostics Market Size, by Product, 2024 Vs. 2031 (USD Million)
Figure 8 Global Rapid Diagnostics Market Size, by Platform, 2024 Vs. 2031 (USD Million)
Figure 9 Global Rapid Diagnostics Market Size, by Application, 2024 Vs. 2031 (USD Million)
Figure 10 Global Rapid Diagnostics Market Size, by Sample Type, 2024 Vs. 2031 (USD Million)
Figure 11 Global Rapid Diagnostics Market Size, by End User, 2024 Vs. 2031 (USD Million)
Figure 12 Global Rapid Diagnostics Market, by Region
Figure 13 Impact Analysis of Market Dynamics
Figure 14 Global Rapid Diagnostics Market Size, by Product, 2024 Vs. 2031 (USD Million)
Figure 15 Global Rapid Diagnostics Market Size, by Platform, 2024 Vs. 2031 (USD Million)
Figure 16 Global Rapid Diagnostics Market Size, by Application, 2024 Vs. 2031 (USD Million)
Figure 17 Global Rapid Diagnostics Market Size, by Sample Type, 2024 Vs. 2031 (USD Million)
Figure 18 Global Rapid Diagnostics Market Size, by End User, 2024 Vs. 2031 (USD Million)
Figure 19 North America: Rapid Diagnostics Market Snapshot
Figure 20 Europe: Rapid Diagnostics Market Snapshot
Figure 21 Asia-Pacific: Rapid Diagnostics Market Snapshot
Figure 22 Latin America: Rapid Diagnostics Market Snapshot
Figure 23 Middle East & Africa: Rapid Diagnostics Market Snapshot
Figure 24 Key Growth Strategies Adopted by Leading Players (2021–2024)
Figure 25 Rapid Diagnostics Market: Competitive Benchmarking, by Application
Figure 26 Rapid Diagnostics Market: Competitive Benchmarking, by Region
Figure 27 Competitive Dashboard Rapid Diagnostics Market
Figure 28 Global Rapid Diagnostics Market Share/Market Ranking Analysis, by Key Players, 2023
Figure 29 Vendor Selection Criteria
Figure 30 Vendor/Brand Analysis
Figure 31 Abbott Laboratories: Financial Overview (2023)
Figure 32 Becton, Dickinson and Company: Financial Overview (2023)
Figure 33 Bio-Rad Laboratories, Inc.: Financial Overview (2023)
Figure 34 F. Hoffmann-La Roche Ltd: Financial Overview (2023)
Figure 35 Danaher Corporation: Financial Overview (2023)
Figure 36 Thermo Fisher Scientific Inc.: Financial Overview (2023)
Figure 37 Biomérieux S.A.: Financial Overview (2023)
Figure 38 Meridian Bioscience, Inc.: Financial Overview (2023)
Figure 39 Trinity Biotech Plc: Financial Overview (2023)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Livestock Diagnostics Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: May-2024
Tuberculosis Diagnostics Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: May-2024
Europe Cancer Diagnostics Market- Opportunity Analysis And Industry Forecast (2024-2031)
Published Date: Feb-2024
Latin America Molecular Diagnostics Market - Opportunity Analysis and Industry Forecasts (2024-2031)
Published Date: Jan-2024
